Results 271 to 280 of about 36,503 (286)

The CYP2C19 Enzyme Polymorphism

Pharmacology, 2000
The genetic test is gradually replacing probe drugs as the primary tool for screening populations for the CYP2C19 polymorphism. A full appreciation for the clinical and toxicological relevance of this genetic variation is presently limited. Further research is needed in several areas.
openaire   +3 more sources

Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

European Journal of Clinical Pharmacology, 2009
To investigate the interaction between allicin and omeprazole and to observe the effects of allicin on CYP2C19 and CYP3A4 activity in healthy Chinese male volunteers with different CYP2C19 genotypes.Eighteen subjects (six CYP2C19*1/CYP2C19*1, four CYP2C19*1/CYP2C19*2, two CYP2C19*1/ CYP2C19*3, and six CYP2C19*2/ CYP2C19*2) were enrolled in a two-phase ...
Yan-Mei Mao, Zhao-Qian Liu, Chun-Ting Han, Dong-Li Hu, Hong-Hao Zhou, Li-Hui Liu, Dong Guo, Li-Jun Yang, Lan Fan, Liang Peng, Zhi-Rong Tan, Dan Wang   +11 more
openaire   +3 more sources

Influence of Azimilide on CYP2C19 Mediated Metabolism

Clinical Pharmacology & Therapeutics, 2003
Clinical Pharmacology & Therapeutics (2003) 73, P32–P32; doi:
Barbara Kuzmak, Anthony J. Destefano, M. El Mouelhi, Gary A. Thompson, Dan Worley   +4 more
openaire   +4 more sources

Duplex genotyping of CYP2C19*2 and CYP2C19*3 by high-resolution melting curve analysis

Hereditas (Beijing), 2013
Clopidogrel is a widely used anti-platelet agent for the prevention of arterial thrombosis. It has been suggested that clopidogrel may be less effective in inhibiting platelet aggregation among patients who are carriers of CYP2C19*2 and CYP2C19*3, two loss-of-function CYP2C19 alleles, which are associated with reduced conversion of clopidogrel to its ...
Hai-Yan Sun, Shi-Ming Wang, Da-Ru Lu, Hong-Yan Chen, Chun-Ge Cao, Fang-Fang Zhou   +5 more
openaire   +5 more sources

CYP2C19 genetic mutations in North Indians

Clinical Pharmacology & Therapeutics, 2000
To identify defective alleles of CYP2C19 (CYP2C19*2 and *3) in North Indians.One hundred extensive metabolizers and 21 poor metabolizers of omeprazole were genotyped with respect to CYP2C19*2 and *3 alleles with polymerase chain reaction-based diagnostic tests.Fifty-two extensive metabolizers and six poor metabolizers were homozygous with the CYP2C19*1/
Krishan K. Kohli, Radha K. Dhiman, Jatinder K. Lamba   +2 more
openaire   +3 more sources

CYP2C19 polymorphism effect on phenobarbitone

European Journal of Clinical Pharmacology, 2000
Objective: The aim of this study was to clarify the effect of genetic polymorphisms of CYP2C19 on the pharmacokinetics of phenobarbitone (PB) using a nonlinear mixed-effects model (NONMEM) analysis in Japanese adults with epilepsy. Methods: A total of 144 serum PB concentrations were obtained from 74 subjects treated with both PB and phenytoin but ...
Eiji Yukawa, Shun Higuchi, Kohsuke Mamiya, A. Hadama, Nobutada Tashiro, Ichiro Ieiri, Kenji Otsubo, Hideaki Ninomiya   +7 more
openaire   +2 more sources

Genetic polymorphism of CYP2C19 in Maharashtrian population

European Journal of Epidemiology, 2007
Inter-individual variability in drug response is well known. Genetic polymorphism in genes encoding drug-metabolizing enzymes results in variation in drug metabolism and in turn drug response. The cytochrome P450 enzymes (CYP) play a central role in the metabolism of many therapeutic agents.
Yashendra Arya, Aditi Chiplunkar, Yogita Ghodke, Bhushan Patwardhan, Pooja Shintre, Anjali Radkar, Kalpana Joshi   +6 more
openaire   +3 more sources

Diazinon Is Activated by CYP2C19 in Human Liver

Toxicology and Applied Pharmacology, 2001
Phosphorothioate compounds are used throughout the world as agricultural and domestic pesticides. Here, the activation of the phosphorothioate diazinon to diazoxon in human liver is described. In an initial study using three human liver microsomal samples, K(m) for diazoxon formation varied markedly (31, 208, and 660 microM; V(max) 1125, 685, and 1028 ...
Alan R. Boobis, Wendela A. Kappers, Robert Edwards, Stephen Murray   +3 more
openaire   +3 more sources

Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele

Clinical and Experimental Pharmacology and Physiology, 2013
Summary The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). Retrospective CYP2C19 phenotyping according to omeprazole : 5‐OH‐omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1,
Pedersen, Rasmus Steen, Nøhr-Jensen, Lene, Brøsen, Kim   +2 more
openaire   +4 more sources

CYP2C19: The Support Crew II

2015
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2C9.
Randal O. Dull, Barbara G. Jericho, Alfredo Aguiar   +2 more
openaire   +2 more sources